Business Context and Reporting Period
Protalix Biotherapeutics, Inc. (PLX) filed this Form 8-K on November 24, 2021, to report the results of a Special Meeting of Stockholders held on the same date. The filing addresses a specific corporate governance matter regarding the potential issuance of shares exceeding 19.99% of the company's pre-transaction outstanding common stock.
Key Financial Metrics
This filing is a current report regarding a stockholder vote and does not contain financial statements. Consequently, the document does not provide data on revenue, profit, cash flow, margins, debt levels, or liquidity metrics. The filing references the company's 7.50% Senior Secured Convertible Notes Due 2024, issued on August 25, 2021, but does not disclose the outstanding principal balance or specific financial terms within this text.
Material Changes
The material event reported is the successful approval by stockholders of a proposal to waive the NYSE American listing standard restriction on issuing shares representing more than 19.99% of the pre-transaction total shares outstanding. This approval is necessary to facilitate potential share issuances resulting from the conversion of, or make-whole payments on, the 7.50% Senior Secured Convertible Notes Due 2024.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the context of the stockholder vote. The primary focus is the procedural outcome of the vote required to satisfy Section 713(a) of the NYSE American Company Guide.
Important Facts for Investors
- Vote Outcome: Stockholders approved the proposal to allow share issuance exceeding 19.99% of pre-transaction outstanding shares.
- Voting Breakdown: 13,697,990 votes were cast in favor, 2,035,098 against, and 160,575 abstentions.
- Underlying Instrument: The approval relates to the 7.50% Senior Secured Convertible Notes Due 2024 issued in August 2021.
- Financial Data: No financial performance metrics (revenue, cash, debt) are disclosed in this specific filing.